Page 4 - Bowel Project News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed. The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 99.7%. Freedom from distant metastasis at 8 years was 97.6% in patients who were clinically and genom...

Memorial Health announces new affiliation Submitted story A new Cancer Center on Memorial’s main campus will improve and enhance the patient experience with communal and private treatment areas featuring natural light and outdoor views. Submitted photo MARYSVILLE – Memorial Health is continuing its focus and dedication to the fight against cancer, with a mission to bring advanced oncology and hematology services to area residents. Two recent developments in this mission include a formal affiliation with The James Cancer Network (JCN), as well as the opening of a new Cancer Center on its...

December 10, 2020 Postmenopausal women may be able to skip some treatments, thereby avoiding some debilitating side effects, new research says.  Roy James Shakespeare/Getty Images It may be possible for some postmenopausal women to avoid some breast cancer treatment without compromising survival, according to two new studies presented at the San Antonio Breast Cancer Symposium (SABCS), hosted by UT Health San Antonio, the American Association for Cancer Research, and the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine. The meeting was held virtually December 8 to 11. ...

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.